Altmann, S.W
Portions feel insufficient
Yes, clinical evidence shows Ozempic (semaglutide) produces 15-22% body weight reduction versus Jardiance's 2-3% average loss
Dawn Addis Legislator So we've got, LAO's office, the California Hospital Association, the California Association of Public Hospitals, the District Hospital Leadership Forum, and then, California Primary Care Association
Consider using CGM to assess glycaemic response to foods (especially if you were glucose dysregulated before) Expected outcomes: Appetite reduction, 25% waist circumference and weight loss, early visceral fat reduction, improved post-meal glucose responses Month 35: Acceleration Phase Reach therapeutic steady GLP-1 dose Use CGM data to guide food choices where necessary Resistance training becomes part of routine and needs to be progressive (ie once strength improves and it becomes easy, lift heavier weights) Waist circumference continues to drop, even if weight remains steady (as muscle weighs more than adipose tissue) Likely improvement in glycaemic and MASLD blood markers Expected outcomes: 510% total body weight loss, increased insulin sensitivity, improved energy levels, lowered blood pressure Month 68: Transition Phase Emphasis shifts to muscle preservation and metabolic independence Protein intake and strength training remain central For those reaching waist goals, begin tapering GLP-1 dose under supervision Expected outcomes: Stable lean mass, reduced visceral fat, better metabolic flexibility, readiness to stop medication How Do We Measure Success
